| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Institute of Pathology [G. K., E. M., K. S., C. D., H. G., M. D.], Department of Surgery [K-J. W.], and Tumor Center [J. B.], Charité University Hospital, Berlin D-10117; Department of Surgery, University Hospital, 01307 Dresden [C. P.]; metaGen Pharmaceuticals, 13347 Berlin [E. D.]; and German Cancer Research Center (DKFZ), 69120 Heidelberg [P. A.], Germany
Purpose: CD24 is expressed in hematological malignancies as well as in a large variety of solid tumors including breast cancer. We aimed to evaluate CD24 protein expression in breast cancer and to correlate to clinicopathological data including patient survival.
Experimental Design: Primary breast carcinomas (201) with a mean clinical follow-up time of 53 months were immunostained using a monoclonal CD24 antibody (Ab-2, clone 24C02). The staining was evaluated as negative versus positive for statistical analysis.
Results: In invasive breast carcinomas, CD24 expression was observed in 84.6% of cases. In univariate survival analyses, a significant association of CD24 expression with shortened patient overall survival (5-year survival rate 91.9% versus 83.8%; P = 0.031; log rank test) and disease-free survival (5-year progression rate 88.3% versus 57.0%; P = 0.0008) was demonstrated. In multivariate analyses CD24, tumor grading and nodal status were significant prognostic parameters for shortened disease-free survival.
Conclusions: Our data suggest that CD24 expression in primary breast cancer as detected by immunohistochemistry might be a new marker for a more aggressive breast cancer biology.
This article has been cited by other articles:
|
|
 |
|
  E. Sagiv, A. Starr, U. Rozovski, R. Khosravi, P. Altevogt, T. Wang, and N. Arber Targeting CD24 for Treatment of Colorectal and Pancreatic Cancer by Monoclonal Antibodies or Small Interfering RNA Cancer Res., April 15, 2008; 68(8): 2803 - 2812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. G. Woo, E. S. Park, J. H. Cheon, J. H. Kim, J.-S. Lee, B. J. Park, W. Kim, S. C. Park, Y. J. Chung, B. G. Kim, et al. Gene Expression-Based Recurrence Prediction of Hepatitis B Virus-Related Human Hepatocellular Carcinoma Clin. Cancer Res., April 1, 2008; 14(7): 2056 - 2064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Y. Chou, Y.-M. Jeng, T.-T. Lee, F.-C. Hu, H.-L. Kao, W.-C. Lin, P.-L. Lai, R.-H. Hu, and R.-H. Yuan Cytoplasmic CD24 Expression Is a Novel Prognostic Factor in Diffuse-Type Gastric Adenocarcinoma Ann. Surg. Oncol., October 1, 2007; 14(10): 2748 - 2758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukushima, T. Tezuka, T. Shimomura, S. Nakano, and H. Kataoka Silencing of Insulin-like Growth Factor-binding Protein-2 in Human Glioblastoma Cells Reduces Both Invasiveness and Expression of Progression-associated Gene CD24 J. Biol. Chem., June 22, 2007; 282(25): 18634 - 18644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Balic, H. Lin, L. Young, D. Hawes, A. Giuliano, G. McNamara, R. H. Datar, and R. J. Cote Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res., October 1, 2006; 12(19): 5615 - 5621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Burkhardt, E Mayordomo, K-J Winzer, F Fritzsche, T Gansukh, S Pahl, W Weichert, C Denkert, H Guski, M Dietel, et al. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer J. Clin. Pathol., April 1, 2006; 59(4): 403 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Fritzsche, E. Dahl, S. Pahl, M. Burkhardt, J. Luo, E. Mayordomo, T. Gansukh, A. Dankof, R. Knuechel, C. Denkert, et al. Prognostic Relevance of AGR2 Expression in Breast Cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1728 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schabath, S. Runz, S. Joumaa, and P. Altevogt CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells J. Cell Sci., January 15, 2006; 119(2): 314 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Baumann, N. Cremers, F. Kroese, G. Orend, R. Chiquet-Ehrismann, T. Uede, H. Yagita, and J. P. Sleeman CD24 Expression Causes the Acquisition of Multiple Cellular Properties Associated with Tumor Growth and Metastasis Cancer Res., December 1, 2005; 65(23): 10783 - 10793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Weichert, C. Denkert, M. Burkhardt, T. Gansukh, J. Bellach, P. Altevogt, M. Dietel, and G. Kristiansen Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival Clin. Cancer Res., September 15, 2005; 11(18): 6574 - 6581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fiume, I. Faenza, A. Matteucci, A. Astolfi, M. Vitale, A. M. Martelli, and L. Cocco Nuclear Phospholipase C {beta}1 (PLC{beta}1) Affects CD24 Expression in Murine Erythroleukemia Cells J. Biol. Chem., June 24, 2005; 280(25): 24221 - 24226. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
